The MERLIN study “Epigenetic changes in umbilical cord mesenchymal stromal cells upon stimulation and culture expansion” has been recently published in Cytotherapy The Journal of Cell Therapy. The body of research by Samantha F.H. de Witte1, Fleur S. Peters1, Ana Merino1, Sander S. Korevaar1, Joyce B.J. van Meurs2, Lisa O’Flynn3, Steve J. Elliman3, Philip N. Newsome4–6, Karin Boer1, Carla C. Baan1 and Martin J. Hoogduijn1 was accepted for publication on May 8, 2018. Cytotherapy is the Official Journal of the International Society for Cellular Therapy (ISCT)
Abstract: Mesenchymal stromal cells (MSCs) are studied for their immunotherapeutic potential. Prior to therapeutic use, MSCs are culture expanded to obtain the required cell numbers and, to improve their efficacy, MSCs may be primed in vitro. Culture expansion and priming induce phenotypical and functional changes in MSCs and thus standardisation and quality control measurements come in need. We investigated the impact of priming and culturing on MSC DNA methylation and examined the use of epigenetic profiling as a quality control tool.
Read about the roles of the partner organizations within MERLIN here.
doi: https://doi.org/10.1016/j.jcyt.2018.05.005 [Epub ahead of print]
Published on June 19, 2018.
Find the link to the paper here.
1Nephrology and Transplantation, 2Endocrinology, Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands; 3Orbsen Therapeutics Ltd., Galway, Ireland; 4National Institute for Health Research Biomedical Research Centre at University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham. 5Centre for Liver Research, Institute of Immunology and Immunotherapy, University of Birmingham. 6Liver Unit, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK